Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean Ching-Yi Tien

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Cell Reports. Medicine|October 1, 2024
Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibitionYu Chang, Xiaoju Wang, Jianzhang Yang, et al.
Nature Genetics|October 3, 2025
Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancerJie Luo, Zhixiang Chen, Yuanyuan Qiao, et al.
The Journal of Clinical Investigation|September 16, 2025
CDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical modelsYi Bao, Yu Chang, Jean Ching-Yi Tien, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 7, 2026
A ligandable PNT domain establishes ERG as a directly targetable oncogenic driver in prostate cancerXiaoju Wang, Wenyan Liu, Jiehao Yang, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 12, 2025
Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinomaJean Ching-Yi Tien, Yali Zhai, Rong Wu, et al.
Cancer Cell|July 19, 2024
Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignanciesTongchen He, Lanbo Xiao, Yuanyuan Qiao, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2020
Targeting transcriptional regulation of SARS-CoV-2 entry factors <i>ACE2</i> and <i>TMPRSS2</i>Yuanyuan Qiao, Xiao-Ming Wang, Rahul Mannan, et al.
Biorxiv : the Preprint Server for Biology|April 2, 2024
<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic LethalityJean Ching-Yi Tien, Yu Chang, Yuping Zhang, et al.
Cell Reports. Medicine|October 5, 2024
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Jean Ching-Yi Tien, Jie Luo, Yu Chang, et al.
Nature Genetics|September 9, 2024
NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesisAbhijit Parolia, Sanjana Eyunni, Brijesh Kumar Verma, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Cell Reports. Medicine|October 1, 2024
Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibitionYu Chang, Xiaoju Wang, Jianzhang Yang, et al.
Nature Genetics|October 3, 2025
Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancerJie Luo, Zhixiang Chen, Yuanyuan Qiao, et al.
The Journal of Clinical Investigation|September 16, 2025
CDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical modelsYi Bao, Yu Chang, Jean Ching-Yi Tien, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 7, 2026
A ligandable PNT domain establishes ERG as a directly targetable oncogenic driver in prostate cancerXiaoju Wang, Wenyan Liu, Jiehao Yang, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 12, 2025
Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinomaJean Ching-Yi Tien, Yali Zhai, Rong Wu, et al.
Cancer Cell|July 19, 2024
Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignanciesTongchen He, Lanbo Xiao, Yuanyuan Qiao, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2020
Targeting transcriptional regulation of SARS-CoV-2 entry factors <i>ACE2</i> and <i>TMPRSS2</i>Yuanyuan Qiao, Xiao-Ming Wang, Rahul Mannan, et al.
Biorxiv : the Preprint Server for Biology|April 2, 2024
<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic LethalityJean Ching-Yi Tien, Yu Chang, Yuping Zhang, et al.
Cell Reports. Medicine|October 5, 2024
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Jean Ching-Yi Tien, Jie Luo, Yu Chang, et al.
Nature Genetics|September 9, 2024
NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesisAbhijit Parolia, Sanjana Eyunni, Brijesh Kumar Verma, et al.
Pageof 3